Literature DB >> 17187438

Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice.

Reiichi Higashiyama1, Yutaka Inagaki, Yun Yu Hong, Miwa Kushida, Sachie Nakao, Maki Niioka, Tetsu Watanabe, Hideyuki Okano, Yumi Matsuzaki, Goshi Shiota, Isao Okazaki.   

Abstract

UNLABELLED: Liver fibrosis is usually progressive, but it can occasionally be reversible if the causative agents are adequately removed or if patients are treated effectively. However, molecular mechanisms responsible for this reversibility of liver fibrosis have been poorly understood. To reveal the contribution of bone marrow (BM)-derived cells to the spontaneous regression of liver fibrosis, mice were treated with repeated carbon tetrachloride injections after hematopoietic reconstitution with enhanced green fluorescent protein (EGFP)-expressing BM cells. The distribution and characteristics of EGFP-positive (EGFP(+)) cells present in fibrotic liver tissue were examined at different time points after cessation of carbon tetrachloride intoxication. A large number of EGFP(+) cells were observed in liver tissue at peak fibrosis, which decreased during the recovery from liver fibrosis. Some of them, as well as EGFP-negative (EGFP(-)) liver resident cells, expressed matrix metalloproteinase (MMP)-13 and MMP-9. Whereas MMP-13 was transiently expressed mainly in the cells clustering in the periportal areas, MMP-9 expression and enzymatic activity were detected over the resolution process in several different kinds of cells located in the portal areas and along the fibrous septa. Therapeutic recruitment of BM cells by granulocyte colony-stimulating factor (G-CSF) treatment significantly enhanced migration of BM-derived cells into fibrotic liver and accelerated the regression of liver fibrosis. Experiments using transgenic mice overexpressing hepatocyte growth factor (HGF) indicated that G-CSF and HGF synergistically increased MMP-9 expression along the fibrous septa.
CONCLUSION: Autologous BM cells contribute to the spontaneous regression of liver fibrosis, and their therapeutic derivation could be a new treatment strategy for intractable liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17187438     DOI: 10.1002/hep.21477

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  91 in total

Review 1.  Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy.

Authors:  Shuji Terai; Haruko Tanimoto; Masaki Maeda; Junichi Zaitsu; Takuro Hisanaga; Takuya Iwamoto; Koichi Fujisawa; Yuko Mizunaga; Toshihiko Matsumoto; Yohei Urata; Yoshio Marumoto; Isao Hidaka; Tsuyoshi Ishikawa; Yuichiro Yokoyama; Koji Aoyama; Masako Tsuchiya; Taro Takami; Kaoru Omori; Naoki Yamamoto; Makoto Segawa; Koichi Uchida; Takahiro Yamasaki; Kiwamu Okita; Isao Sakaida
Journal:  J Gastroenterol       Date:  2012-04-05       Impact factor: 7.527

Review 2.  Recent advances in the pathogenesis and diagnosis of liver fibrosis.

Authors:  Natalie J Török
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

Review 3.  Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches.

Authors:  Elisabetta Mormone; Joseph George; Natalia Nieto
Journal:  Chem Biol Interact       Date:  2011-07-22       Impact factor: 5.192

4.  Pathological and MR-DWI study of the acute hepatic injury model after stem cell transplantation.

Authors:  Quan-Liang Shang; En-Hua Xiao; Qi-Chang Zhou; Jian-Guang Luo; Hai-Jun Wu
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

Review 5.  Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.

Authors:  Fernando Ezquer; Flavia Bruna; Sebastián Calligaris; Paulette Conget; Marcelo Ezquer
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

6.  Antifibrotic Activity of Human Placental Amnion Membrane-Derived CD34+ Mesenchymal Stem/Progenitor Cell Transplantation in Mice With Thioacetamide-Induced Liver Injury.

Authors:  Po-Huang Lee; Chi-Tang Tu; Chih-Chiang Hsiao; Ming-Song Tsai; Cheng-Maw Ho; Nai-Chen Cheng; Tzu-Min Hung; Daniel Tzu-Bi Shih
Journal:  Stem Cells Transl Med       Date:  2016-07-12       Impact factor: 6.940

7.  Therapy with bone marrow cells reduces liver alterations in mice chronically infected by Schistosoma mansoni.

Authors:  Sheilla Andrade Oliveira; Bruno-Solano-Freitas Souza; Carla-Adriana Guimaraes-Ferreira; Elton-Sa Barreto; Siane-Campos Souza; Luiz-Antonio-Rodrigues Freitas; Ricardo Ribeiro-Dos-Santos; Milena-Botelho-Pereira Soares
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

Review 8.  Stem cells in liver regeneration and their potential clinical applications.

Authors:  Ioannis Drosos; George Kolios
Journal:  Stem Cell Rev Rep       Date:  2013-10       Impact factor: 5.739

9.  Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma.

Authors:  Jeffrey M Vainshtein; Rafi Kabarriti; Keyur J Mehta; Jayanta Roy-Chowdhury; Chandan Guha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038

10.  Notch-RBP-J signaling regulates the mobilization and function of endothelial progenitor cells by dynamic modulation of CXCR4 expression in mice.

Authors:  Lin Wang; Yao-Chun Wang; Xing-Bin Hu; Bing-Fang Zhang; Guo-Rui Dou; Fei He; Fang Gao; Fan Feng; Ying-Min Liang; Ke-Feng Dou; Hua Han
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.